Physician profile
Chandranni Quinones
NPI 1588753800
$5,798.51
in general payments reported to CMS, 2019-2025
28 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 94% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $570 · 2022: $1,072 · 2023: $1,383 · 2024: $1,170 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,042 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,041.98 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.54 | 2021-2025 | |
| Janssen Biotech, INC. | $646.04 | 2021-2025 | Tremfya |
| Ucb, INC. | $483.24 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $468.47 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $323.02 | 2021-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $304.79 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $251.88 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $243.59 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $241.47 | 2022-2025 | |
| Amgen INC. | $229.38 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $226.78 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $175.19 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $175.01 | 2022-2025 | |
| Almirall LLC | $155.97 | 2021-2024 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $139.45 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $94.86 | 2021-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.55 | 2023-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $88.30 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $88.26 | 2021-2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $80.49 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $48.31 | 2022 | |
| Epi Health, LLC | $45.86 | 2022 | |
| Biofrontera INC. | $36.79 | 2022 | |
| Ani Pharmaceuticals, INC. | $32.16 | 2022-2023 | Purified Cortrophin Gel |
| Verrica Pharmaceuticals INC. | $18.69 | 2023 | Ycanth |
| Dermira, INC. | $17.27 | 2021 | |
| Lnhc, INC | $16.03 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandranni Quinones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.